← Back to Search

Immunomodulatory Agent

Iberdomide for Kidney Failure

Phase 1
Waitlist Available
Research Sponsored by Celgene
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 72 hours following the last dose of iberdomide
Awards & highlights
No Placebo-Only Group

Summary

This trial tests iberdomide, a medication, in people with severe kidney problems, those on dialysis, and those with normal kidney function. It aims to see how the drug is processed differently in these groups.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 72 hours following the last dose of iberdomide
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 72 hours following the last dose of iberdomide for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Iberdomide Pharmacokinetics - AUC(0-T)
Iberdomide Pharmacokinetics - AUC(INF)
Iberdomide Pharmacokinetics - CLD
+13 more
Secondary study objectives
Incidence of Adverse Events (AEs)

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

3Treatment groups
Experimental Treatment
Group I: Group 3: Participants with normal renal functionExperimental Treatment1 Intervention
Normal renal function, as defined by a creatinine clearance (Clcr) \> 90 mL/min estimated using the Cockcroft-Gault (C-G) equation, at screening.
Group II: Group 2: Participants with kidney failure who are on intermittent hemodialysis (IHD)Experimental Treatment1 Intervention
Kidney failure participants on intermittent hemodialysis (IHD)
Group III: Group 1: Participants with severe Renal Impairment (RI)Experimental Treatment1 Intervention
Severe Renal Impairment (RI), as defined by an eGFR \< 30 mL/min/1.73 m2 and not requiring dialysis, at screening
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
CC-220
Not yet FDA approved

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

CelgeneLead Sponsor
645 Previous Clinical Trials
130,414 Total Patients Enrolled
Alice Wang, MDStudy DirectorCelgene Corporation
1 Previous Clinical Trials
40 Total Patients Enrolled
Bristol-Myers SquibbStudy DirectorBristol-Myers Squibb
1,566 Previous Clinical Trials
3,384,499 Total Patients Enrolled
2 Trials studying Kidney Failure
78 Patients Enrolled for Kidney Failure
~6 spots leftby Oct 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top